| Hazard Information | Back Directory | [Uses]
NY0116 is a neuromedin U receptor 2 (NMUR2) agonist with EC50 values of 27.76 μM for hNMUR1 and 13.61 μM for hNMUR2. NY0116 decreases cAMP while stimulating calcium signaling in stably expressing NMUR2 HEK293 cells[1]. | [in vivo]
NY0116 (3-30 mg/kg; SC; ; for 14 days) decreases bodyweight, visceral adipose tissue, and cholesterol on a high‐fat diet[1]. | Animal Model: | Male diet induced obese (DIO) C57BL/6J mice age 18 weeks and 8 age[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | Subcutaneous injection; for 14 days | | Result: | Significantly decreased bodyweight compared to vehicle, whereas mice were maintained on a high-fat diet. |
| [References]
[1] Catherine M Sampson, et al. Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models. Pharmacol Res Perspect. 2018 Aug 23;6(5):e00425. DOI:10.1002/prp2.425 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|